A multicenter comparison of the safety of oral versus intravenous acetylcysteine for treatment of acetaminophen overdose

Oral and intravenous (IV) N-acetylcysteine (NAC) are used for the treatment of acetaminophen poisoning. The objective of this multicenter study was to compare the safety of these two routes of administration. Methods. We conducted a multicenter chart review of all patients treated with NAC for aceta...

Full description

Saved in:
Bibliographic Details
Published inClinical toxicology (Philadelphia, Pa.) Vol. 48; no. 5; pp. 424 - 430
Main Authors Bebarta, Vikhyat S, Kao, Louise, Froberg, Blake, Clark, Richard F, Lavonas, Eric, Qi, Ming, Delgado, Joao, McDonagh, John, Arnold, Tom, Odujebe, Oladapo, O'Malley, Gerry, Lares, Claudia, Aguilera, Elizabeth, Dart, Richard, Heard, Kennon, Stanford, Chriss, Kokko, Jamie, Bogdan, Greg, Mendoza, Carrie, Mlynarchek, Sara, Rhyee, Sean, Hoppe, Jason, Haur, William, Tan, Hock Heng, Tran, Nguyen Nguyen, Varney, Shawn, Zosel, Amy, Buchanan, Jennifer, Al-Helial, Mohammed
Format Journal Article
LanguageEnglish
Published England Informa UK Ltd 01.06.2010
Taylor & Francis
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Oral and intravenous (IV) N-acetylcysteine (NAC) are used for the treatment of acetaminophen poisoning. The objective of this multicenter study was to compare the safety of these two routes of administration. Methods. We conducted a multicenter chart review of all patients treated with NAC for acetaminophen poisoning. The primary safety outcome was the percentage of patients with NAC-related adverse events. Results. A total of 503 subjects were included in the safety analysis (306 IV-only, 145 oral-only, and 52 both routes). There were no serious adverse events related to NAC for either route. Nausea and vomiting were the most common related adverse events and were more common with oral treatment (23 vs. 9%). Anaphylactoid reactions were more common with IV administration (6 vs. 2%). Conclusions. IV and oral NAC are generally mild adverse drug reactions.
ISSN:1556-3650
1556-9519
DOI:10.3109/15563650.2010.486381